ClinicalTrials.gg

Kidney Failure, Chronic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 2,112 studies for Kidney Failure, Chronic across more than 10 countries. 274 are recruiting or about to start. 1,649 of them are mainly about Kidney Failure, Chronic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 5,336 studies for Kidney Failure, Chronic. How that becomes 2,112 here

This page counts the studies the registry files under Kidney Failure, Chronic, and those it files under no condition that list Kidney Failure, Chronicthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 5,336Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −182List Kidney Failure, Chronic as a condition, but the registry did not file them under itMost often written as “End Stage Renal Failure on Dialysis” (30), “Renal Failure Chronic” (18), and “End Stage Renal Disease on Dialysis” (18). The registry filed them under other conditions only, most often Renal Insufficiency, Chronic (104) and Renal Insufficiency (18).
  3. −3,047Match it another way216 name it in the title, 4 in a keyword, and 2,827 by a synonym or other text the search reads.
  4. 2,107Counted here and found by its search98 of them list Kidney Failure, Chronic in their own words; the registry filed them under no condition.
  5. +5
    Counted here, but its search does not find them
  6. 2,112The count on this page

Status

Completed
1,274
Status unknown
266
Recruiting
169
Terminated
139
Not yet recruiting
86
Active, not recruiting
83

Phase

Phase 2
283
Phase 4
244
Phase 3
203
Phase 1
188
Early Phase 1
10

Where

United States
765
France
145
Canada
134
China
114
Germany
109
United Kingdom
103

Who develops what

Add Kidney Failure, Chronic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 15 companies, 18 with this as their studies’ main aim; 2 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Regeneron Pharmaceuticals, Bristol-Myers Squibb and Eli Lilly here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TacrolimusRecent, limited
Evidence
  • NCT07835581 · Eledon Pharmaceuticals · Phase 3 · live · comparator · “Tacrolimus” · registered Sep 2026
  • NCT06126380 · Eledon Pharmaceuticals · Phase 2 · live · comparator · “Tacrolimus” · registered Nov 2023
  • NCT05983770 · Eledon Pharmaceuticals · Phase 2 · comparator · “Tacrolimus” · registered Aug 2023
  • NCT03099122 · Sanofi · Phase 4 · background · “Tacrolimus” · registered Mar 2017
  • NCT02432833 · chiesi farmaceutici · Phase 4 · comparator · “PROGRAF®” · registered Apr 2015
Astellas Pharma Inc62% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 1 generic authorized13 studies
Epoetin AlfaEarlier only
Evidence
  • NCT03408639 · Cinnagen · Phase 3 · comparator · “Eprex®” · registered Dec 2017
  • NCT02586402 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · comparator · “Epoetin Alfa” · registered Oct 2015
  • NCT02278341 · Astellas Pharma Inc · Phase 3 · comparator · “Epoetin alfa” · registered Oct 2014
  • NCT02273726 · Kyntra Bio · Phase 3 · comparator · “Epoetin Alfa” · registered Oct 2014
  • NCT02052310 · Kyntra Bio · Phase 3 · comparator · “Epoetin Alfa” · registered Jan 2014
Johnson & Johnson55% of its industry studiesUS: Amgen (FDA 1989) + 1 otherEU: Hoffmann-La Roche (EMA 1997) + 6 others00 studies
SevelamerEarlier only
Evidence
  • NCT04456803 · Sinomune Pharmaceutical Co., Ltd · Phase 3 · comparator · “Sevelamer carbonate tablet” · registered Jun 2020
  • NCT03988920 · Ardelyx · Phase 4 · background · “Sevelamer Carbonate” · registered Jun 2019
  • NCT03984760 · Panion & BF Biotech Inc. · Phase 3 · comparator · “Sevelamer Carbonate” · registered Jun 2019
  • NCT00844662 · Ineos Healthcare Limited · Phase 3 · comparator · “Sevelamer hydrochloride” · registered Feb 2009
  • NCT00436683 · Ineos Healthcare Limited · Phase 2 · comparator · “Sevelamer HCl” · registered Feb 2007
Sanofi71% of its industry studiesEU: Sanofi (EMA 2000)00 studies

5 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tegoprubart☆ Track1 live phase-3 study: NCT07835581Eledon Pharmaceuticals
CSL300☆ Track1 live phase-3 study: NCT05485961CSL Limited

The 2 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.tegoprubart · Eledon Pharmaceuticals · Phase 2 main aimNCT05027906 Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — primary endpoint: Safety Incidences · 48 enrolled
  • Mar 2027 est.Budesonide · calliditas therapeutics ab · Phase 4 registry mapping onlyNCT06712407 Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy — primary endpoint: Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to Baseline · 60 enrolled
  • 8 Mar 2027 est.AZD7760 · AstraZeneca · Phase 2 named, not the main aimNCT06749457 A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) — primary endpoint: Phase I: Occurence of adverse events (AEs) · 242 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Kidney Failure, Chronic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 6 open · Diuretics 2 open · Factor Xa inhibitors 2 open · Calcineurin inhibitors 1 open · Mineralocorticoid receptor antagonists (MRAs) 1 open

Coming up

125studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger. 18 (11%) take children under 18. 0 (0%) are for women only and 1 (1%) for men only; 22 (13%) take healthy volunteers.

Recruiting studies that take each age, of 169
AgeWomenMen
1011 (7%)12 (7%)
18148 (88%)148 (88%)
30160 (95%)160 (95%)
40162 (96%)162 (96%)
50163 (96%)163 (96%)
65160 (95%)160 (95%)
75147 (87%)147 (87%)
85123 (73%)123 (73%)

Across all 2,112 studies, recruiting or not: 20% stop at 75 or younger and 9% at 65; 9% take children; <1% are for women only and 1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Kidney Failure, Chronic studies take

Of 67 phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 112 mo5–27 · 67 studies7 mo5–16 · 46 studies—
Phase 1/235 mo25–54 · 29 studies——
Phase 232 mo17–55 · 67 studies24 mo17–56 · 26 studies35 mo25–52 · 41 studies
Phase 332 mo21–48 · 66 studies30 mo20–40 · 42 studies—
Phase 431 mo16–54 · 63 studies—37 mo17–80 · 52 studies
Interventional, no phase22 mo8–45 · 427 studies18 mo8–40 · 78 studies23 mo8–47 · 349 studies
Observational29 mo11–62 · 150 studies—30 mo11–62 · 131 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered15

Show 10 more

Studies

Recruiting first, then most recently updated. Showing 50 of 2,112. Browse all 2,112 → or search them.